BX U004
Alternative Names: BX-U004Latest Information Update: 28 Aug 2023
Price :
$50 *
At a glance
- Originator Baylx
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cirrhosis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Liver-Cirrhosis in USA (Parenteral)
- 17 Jul 2019 Baylx has patent protection for human umbilical cord-derived mesenchymal stem cells based technology (Baylx pipeline, July 2019)
- 01 Jul 2019 Preclinical trials in Liver cirrhosis in USA (Parenteral) before July 2019 (Baylx pipeline, July 2019)